The genetic variability of CRC makes necessary to identify the tumor subtypes (e.g., mismatch repair or microsatellite instability status, mutations in KRAS, NRAS, BRAF) to set the most suitable adjuvant therapy (i.e., systemic chemotherapy alone or with other FDA-approved drugs). The gene discussed is BRAF; the disease is colorectal carcinoma.